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Abstract 
Intrauterine growth restriction (IUGR) is associated with significantly increased perinatal morbidity and 
mortality as well as cardiovascular disease and glucose intolerance in adult life. A number of disorders from 
genetic to metabolic, vascular, coagulative, autoimmune, as well as infectious, can influence fetal growth by 
damaging the placenta, leading to IUGR as a result of many possible fetal, placental and maternal disorders. 
Strict definitions of IUGR and of its severity are needed in order to eventually distinguish among different 
phenotypes, such as gestational age at onset, degree of growth restriction and presence of hypoxia. 
This report explores and reviews some of the most recent developments in both clinical and basic research on 
intrauterine growth restriction, by seeking mechanisms that involve genetic factors, utero-placental nutrient 
availability and vascular growth factors. 
New exciting findings on the genomic imprinting defects potentially associated with IUGR, and the placental 
anomalies associated with the decreased nutrient transport are summarized. Moreover, recent data on angiogenic 
growth factors as well as new information arising from application of gene chip technologies are discussed. 
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INTRODUCTION 
Intrauterine growth restriction (IUGR) presents a complex management problem for the clinician. The failure of 
a fetus to achieve its genetically determined growth potential is associated with significantly increased perinatal 
morbidity and mortality [1] as well as being a major determinant of cardiovascular disease and glucose 
intolerance in adult life [2]. 
IUGR is not a specific disease entity with a unique pathophysiology, but the result of suboptimal intrauterine 
growth conditions in conjunction with a variety of disorders from genetic to metabolic, vascular, coagulative, 
autoimmune, as well as infectious. New challenging fields, like genomic imprinting defects potentially involved 
in regulation of fetal and placental growth, or trombophilic diseases potentially damaging the placenta are now 
being explored and may represent additional causes of IUGR. 
Understanding the etiology of IUGR in each specific pregnancy is the basis for the clinical management of that 
patient. Fetal growth is a complex process regulated by genetic factors, utero-placental nutrient availability and 
hormones. However, independently from the underlying cause, a fetus that fails to achieve its full growth 
potential has, by definition, undergone a process of reduced tissue deposition due to a reduced nutritional supply 
from the utero-placental circulation (Figure 1). While the knowledge of IUGR resulting from a shallow 
trophoblast invasion during the first trimester, together with Doppler studies showing changes in the utero-
placental circulation, is widespread among both clinicians and scientists, the discoveries that the nutrient supply 
can also be decreased by changes in the placental transport properties is not so well known. Moreover, recent 
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studies in a number of mouse knockout and transgenic models have allowed to link defects in imprinted genes to 
changes in specific transport systems [3]. However, the lessons of the murine experiments need to be compared 
to results obtained in human pregnancies. We will briefly review some of the most recent developments in both 
clinical and basic research on intrauterine growth restriction. In particular, we will describe advances in clinical 
understanding of the natural history of IUGR, the genomic imprinting defects potentially associated with IUGR, 
and the placental anomalies possibly responsible for the decreased nutrient transport. We will also summarize 
new results demonstrating involvement of angiogenic growth factors in the pathogenesis of preeclampsia and 
IUGR. 
Figure 1: Mechanisms for reduced tissue deposition in fetal growth restriction. 
 
 
CRITERIA FOR DIAGNOSIS AND EVALUATION OF SEVERITY OF IUGR 
There is still considerable debate as to how IUGR should be defined. The most commonly used definition is 
based on a birth weight below the 10th percentile. However, a significant number of small-for-gestational age 
babies (SGA) is not truly growth restricted and is instead part of the normal variation in the birth weight 
distribution. Therefore, we should include the evaluation of growth in utero, for example as a defined shift in 
centiles on a standard growth curve of the routine ultrasound measurements in the definition of a population of 
truly growth-restricted fetuses. However, in large population studies, in utero diagnosis might not be available, 
and a population of SGA is often utilized. This is acceptable as long as explained and recognized as a study 
limitation. 
Assessment of intrauterine growth is particularly relevant for diagnosis of IUGR early in gestation. Diagnosis of 
IUGR during pregnancy before 32 weeks of gestation might result in babies having a weight over the 10th 
percentile at birth. There are two potential reasons for this discrepancy. 1. In conventional birth weight curves, 
the assumption that the weight-for-gestation profile of babies born prematurely represents that of the healthy 
babies who continue to grow in utero might be incorrect [4].  2. Alterations in growth occurring early in 
gestation might lead to a very sick baby before the weight falls below the 10th centile. 
This again underlines the need for endpoints that allow for definitions of severity. There are three main general 
determinants of severity: 1. gestational age, 2. degree of nutritional deprivation, and 3. degree of oxygenation. 
All these parameters are associated with short- and long-term adverse outcome. However, the prognosis for 
neurological function is strictly related to oxygenation and adequate timing of delivery. Not all IUGR fetuses are 
subjected to a reduced oxygen supply [5]. Fetuses that exhibit normal umbilical arterial blood flows evaluated by 
Doppler blood velocimetry and normal fetal heart rate are indeed associated with normal oxygenation [5]. 
Recently, a temporal sequence of early and late Doppler velocimetry alterations which occur in a subset of early 
and severe IUGR fetuses has been described [6]. Abnormalities of the pulsatility index of the middle cerebral 
artery and of the umbilical artery (absent end diastolic flow) represent early changes that precede blood flow 
abnormalities of the ductus venosus, reverse end-diastolic flow of the umbilical artery, decreased pulmonary 
artery peak velocity, reverse flow in the ductus venosus and, lastly, decreased aortic peak velocity, which 
represent "late" changes, associated with an increased risk of perinatal death [6]. 
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GENOMIC IMPRINTING DEFECTS AND IUGR 
There is a strong association between abnormal fetal karyotype, Mendelian single gene disorders, uniparental 
disomies (UPDs) and IUGR. Fetal genetic changes include trisomies of chromosomes 13, 18 and 21, 
microdeletions, confined placental mosaicism and more than 50 inherited single gene disorders. The risks 
associated with UPDs include genetic dysfunction if the chromosomal segment involved harbours imprinted 
genes. IUGR is the most common feature, a phenotype shared among matUPD7, matUPD14, patUPD6q24 and 
matUPD20. The fetal growth disturbance in UPD carriers is consistent with the action of imprinted genes during 
fetal growth, as recently reviewed [7]. In murine models, most of the 60 recognized imprinted genes are 
expressed during fetal life and, in particular, in the placenta, in which they may regulate fetal demand and 
maternal supply of nutrients. This peculiar mechanism of growth regulation has been demonstrated for Igf2 in 
mice lacking specific Igf2 placental transcript [3]. 
There are many mouse models in which targeted candidate gene mutations result in compromised placental 
function and IUGR, although the pathological effects differ among the investigated genes. ESX1 mutants show 
changes of vascularization in the placental labyrinth [8], Igf2 null mice have an inefficient placental transport 
[3], and p57/Kip2-deficient mice present changes of labyrinth and spongiotrophoblast [9]. Data from murine 
models strongly indicate that IUGR cannot be considered a disease per se, rather a manifestation of many 
possible fetal gene defects that primarily affect placental development and function. The reverse approach (from 
phenotype to gene defect) aimed to demonstrate that genetic lesions in human IUGR fetuses are complicated by 
the heterogeneity of predisposing causes. A useful approach could be to segregate the IUGR cases in different 
sub-phenotypes, as recently suggested by Cross [10] for human preeclampsia. In this view it could be helpful to 
evaluate the severity of IUGR [5], placental morphology and additional pregnancy complications such as 
preeclampsia. Finally, in order to focus on possible genetic causes of IUGR it is important to take into account 
and investigate a familial aggregation of IUGR by assessing a detailed pedigree analysis. 
PLACENTAL TRANSPORT 
In the human placenta, it is the two plasma membranes of the syncytiotrophoblast that represent the primary 
barrier to transport of glucose, amino acids and most ions. Consequently, studies of isolated microvillous 
(MVM) and basal plasma membranes (BM) may provide valuable information concerning transplacental 
transport processes. In MVM isolated from small-for gestational age babies the activity of the amino acid 
transporter system A was shown to be markedly reduced [11]. Intrauterine growth restriction is also associated 
with a reduced activity/expression of placental transport systems for essential amino acids, such as taurine, 
leucine and cationic amino acids. In contrast to the effect of IUGR on placental amino acid transport the 
expression and activity of glucose transporters is unaltered in IUGR [12]. 
Placental ion transporters also appear to be altered in IUGR. For example, the activity and protein expression of 
the Na+/ K+ ATPase in the MVM, but not BM, is reduced in the IUGR placenta [13]. It is possible that this 
change may impair the ability of the syncytiotrophoblast to maintain a low intracellular Na+ concentration, 
thereby affecting all Na+-coupled transport processes. Furthermore, the activity and protein expression of the 
Na+/H+ exchanger in MVM, the primary mechanism for syncytiotrophoblast pH regulation, is diminished in 
preterm, but not in term IUGR [14]. It is speculated that these alterations may contribute to the development of 
acidosis in the IUGR fetus delivered preterm. Interestingly, the activity of the Ca2+ ATPase in BM has been 
shown to be markedly increased in association with IUGR [15]. 
Collectively, these in vitro data clearly suggest that IUGR is associated with a number of changes in the activity 
and/or expression of placental nutrient and ion transporters. These alterations may be present also in vivo as 
shown by the recent demonstration of decreased transplacental transport of leucine in human pregnancies 
complicated by IUGR [16]. 
The changes observed in IUGR are likely to be specific and not secondary to a general pathological process such 
as altered membrane composition. Some of the observed changes, for example, the reduction in amino acid 
transporter activity, may be "primary" events in the development of IUGR whereas other alterations, e.g., 
increased Ca2+ ATPase activity, may be secondary to restricted fetal growth. There are also new possibilities 
emerging as the molecular characterization of nutrient transporters progresses. For both glucose and amino acid 
transporters the concept of a single transporter is being displaced as multiple isoforms of a transporter are 
defined. If these isoforms have different properties, altered isoform ratios or distribution may have significant 
effects on activity in vivo. For example the system L amino acids transporter has two isoforms; the first, LAT-1, 
is an exchange transporter [17], while there are reports that the second, LAT-2, is a uniporter [18]. Changes in 
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the isoform ratio might have significant effects on transport without apparent changes in overall transporter 
expression. 
It is speculated that the placenta functions as a "nutritional sensor" and responds to changes in maternal nutrition 
or placental blood flow by altering the activity and/or expression of placental nutrient transporters, thereby 
regulating fetal growth. There is however an equally powerful argument to be made that the fetus, as the "end-
user" of nutrients transported across the placenta, may also act as the nutritional sensor through output of 
hormones controlling fetal (and possibly placental) growth by circulating nutrient concentrations. 
EXPRESSION OF VEGF, PlGF AND THEIR RECEPTORS IN PREGNANCIES COMPLICATED BY 
PREECLAMPSIA AND IUGR 
Several growth factors such as vascular endothelial growth factor (VEGF-A) and placental growth factor (PlGF) 
are involved in placental vascular development. Therefore, it is of interest to understand whether dysregulation 
in the VEGF family may be associated with preeclampsia and IUGR. Recent studies show evidence for a 
significant deregulation of the expression of VEGF, PlGF and their receptors in the placenta of severe early onset 
preeclampsia or IUGR [19]. 
VEGF-A, PlGF and VEGFR-1 that are produced by villous and extravillous trophoblast cells are significantly 
upregulated in placentas from preeclamptic women and from cases with IUGR [19,20]. It seems that during 
pregnancy most of the circulating VEGF is bound to sVEGFR-1 produced in high amounts by the placenta [19-
21]. In preeclampsia, placental production of VEGFR-1 and sVEGFR-1 is likely increased because of low 
oxygen levels in the placenta. The massive increase of sVEGFR-1 in preeclamptic women results in low levels 
of circulating free VEGF and free PlGF. 
Results from the placental bed biopsies show that VEGFR-1 expression is significantly reduced in cases with 
preeclampsia. Low levels of VEGFR-1 in the placental bed may explain the defective uterine vascularization 
frequently associated with early onset preeclampsia. Maynard et al. [20] have shown in a rodent model that 
VEGF, PlGF and sVEGFR-1 are likely to play a role in the pathogenesis of preeclampsia. Excess placental 
production of sVEGFR-1 contributes to hypertension, proteinuria and glomerular endotheliosis. 
In conclusion, these studies indicate the involvement of sVEGFR-1 as an antagonist to VEGF and PlGF in 
preeclampsia. The downregulation of the membrane bound form of VEGFR-1 in the placental bed may also 
result in the decreased maternal vascular adaptation to pregnancy. 
NEW DEVELOPMENTS OF THE GENE CHIP STUDIES APPROACH 
New areas, like gene chip studies fishing for new genes, are exploring still unknown possibilities. These 
preliminary studies reveal that genes involved in lipid metabolism are being differentially upregulated in the 
growth-restricted group. Moreover, few other genes that have not been associated with IUGR before have been 
found to have expression levels that are markedly different in IUGR. 
Aberrant gene expression in the placenta of IUGR pregnancies has been investigated on pooled RNA purified 
from tissue biopsies taken at term [22]. The expression profiles have been analysed by microarrays (Human 
Genome U133A, Affimetrix) and the expression levels of a selection of genes verified by real-time PCR. A 
number of genes implicated in lipid metabolism were differentially expressed in IUGR placentas. Among these, 
lipoprotein receptors (VLDL-ApoE), lipoprotein lipase (LPL), fatty acid-binding protein 4 (FABP4) and 
intracellular lipase activities are involved in the transport of fatty acids from the maternal circulation across the 
placenta. These changes might therefore modify the placental delivery of fatty acids to the fetus in a critical 
period when fat is deposited exponentially. This is in agreement with the different profile of polyunsaturated 
fatty acids that has been reported in IUGR [23]. 
sVEGFR has also been found to be upregulated in cases of IUGR. Soluble VEGFR has a higher affinity for 
VEGF than VEGFR and it has been hypothesized that it may function as an inhibitor of the cellular VEGF 
response [24]. This study also identified caveolins as potential factors implicated in IUGR. 
Further investigations are needed to detail the significance and the role of the differentially expressed genes 
identified by the array analysis. In particular, two main issues are under discussion: technical relevance and 
placental function. The first issue challenges the reproducibility, sensitivity and accuracy of microarray results. 
One major concern is the variability of tissue biopsies, which is intrinsic to tissue heterogeneity but also results 
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from sampling procedures. This is particularly relevant for the human placenta at term because of its size and 
composite structure. Hence, multiple variables have to be taken into account when comparing microarray results 
either from intra-experiments as well as results from different investigators. Phenotype classification and 
analytical strategy should also be taken into account since they determine the final number of genes eligible for 
comparison, a variable that happens to vary tremendously (from less than ten to several hundred genes) 
depending on investigators, experimental settings and procedures. 
The second main issue is regarding the functional significance of the genes whose expression is reported to be 
modified in placenta of growth-restricted fetuses. Three of these genes are involved in the transport of fatty acids 
from the maternal circulation across the placenta. Since the changes suggest an increased supply of fatty acids to 
the fetus in spite of low fetal adiposity and despite results in vivo demonstrating reduced feto-maternal 
relationships for the long-chain polyunsaturated fatty acids [23], the question arises whether this could represent 
an adaptation of placental transfer function to compensate for poor fetal growth. Whether compensatory 
mechanisms should be regarded as tentative explanations when experimental results are contrary to 
physiological/biochemical expectations is a matter of debate. 
CONCLUSIONS 
In the last decades, thanks to new technologies like ultrasound and fetal blood sampling we have learned a lot 
more about development of the fetus and abnormalities of its growth trajectory leading to IUGR. Moreover, the 
placental mechanisms involved in this pathology are starting to be understood. However, although this progress 
has led to improvements in diagnosis and understanding, we are still in the situation of no reasonable therapy 
during pregnancy, optimal timing of delivery still representing the only available intervention in order to reduce 
adverse pregnancy outcomes. Further efforts are needed to utilize this body of new information in the 
development of novel therapeutic strategies. 
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